| Assessment Status | Rapid Review Complete |
| HTA ID | 25010 |
| Drug | Durvalumab |
| Brand | Imfinzi® |
| Indication | Durvalumab (Imfinzi®) is indicated as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy. |
| Assessment Process | |
| Rapid review commissioned | 14/02/2025 |
| Rapid review completed | 06/03/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care. |
